SA
MDGL icon

Sanctuary Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sanctuary Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
1,120
-80
-7% -$41K ﹤0.01% 1842
2026
Q1 		$628K Sell
1,200
-171
-12% -$81.7K ﹤0.01% 1630
2025
Q4 		$798K Sell
1,371
-94
-6% -$48K ﹤0.01% 1451
2025
Q3 		$672K Buy
1,465
+192
+15% +$71.6K ﹤0.01% 1515
2025
Q2 		$385K Sell
1,273
-128
-9% -$38.1K ﹤0.01% 1772
2025
Q1 		$464K Buy
1,401
+154
+12% +$50.6K ﹤0.01% 1558
2024
Q4 		$422K Buy
1,247
+62
+5% +$17.4K ﹤0.01% 1795
2024
Q3 		$412K Buy
1,185
+134
+13% +$34.3K ﹤0.01% 1816
2024
Q2 		$203K Buy
+1,051
New +$250K ﹤0.01% 2180

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sanctuary Advisors's MDGL Position: Q2 2026 in Review

Sanctuary Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 6.7% in Q2 2026, selling an estimated $41K and leaving 1,120 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Sanctuary Advisors first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $798K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Sanctuary Advisors held 1,120 shares of Madrigal Pharmaceuticals worth $601K as of Q2 2026.
  • Sanctuary Advisors sold 80 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $41K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1842 holding.
  • Sanctuary Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Sanctuary Advisors's Madrigal Pharmaceuticals position peaked at $798K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.